Hepion Pharmaceuticals raises $5.0M in registered direct offering with warrants

Hepion Pharmaceuticals, Inc.

Gross proceeds $5.0M from sale of 980,393 shares (or equivalents) at $5.10/share plus warrants.
Series A and B warrants to buy up to 980,393 shares each at $4.85; Series A expires in 5 yrs, Series B in 1.5 yrs.
Closing expected on or about Oct 3, 2023; A.G.P./Alliance Global Partners as placement agent.
Net proceeds intended for clinical development and working capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Hepion Pharmaceuticals, Inc. entered into Purchase Agreement with an institutional investor valued at approximately $5.0 million (effective 2023-09-28).

Action: entry
Agreement: equity purchase
Counterparty: an institutional investor
Value: approximately $5.0 million
Effective: 2023-09-28

Exact text from the filing

On September 28, 2023, Hepion Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional investor, pursuant to which the Company agreed to issue and sell to such investor, in a registered direct offering (i) 400,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $5.10 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 580,393 shares of the Company’s Common Stock at an exercise price of $0.0001 per share at an offering price of $5.09 per share.

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-106030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.